T lymphocyte de novo purine synthesis pathway

The "T lymphocyte proliferation pathway via purine synthesis inhibition by azathioprine/mercaptopurines/metabolites thereof" refers not to a single molecular target but rather to the collective set of enzymes and metabolic steps involved in the de novo biosynthesis of purines within activated T cells. This metabolic process is essential for providing nucleotides required for DNA and RNA synthesis during rapid clonal expansion following immune activation[1][2]. Drugs such as azathioprine and 6‑mercaptopurine act as antimetabolites that inhibit key enzymes within this pathway—most notably inosine monophosphate dehydrogenase (IMPDH)—thereby reducing guanine nucleotide pools, arresting the cell cycle, inducing apoptosis in cycling cells, and ultimately suppressing immune responses[1][2]. These drugs are widely used as immunosuppressants in autoimmune diseases and organ transplantation. However, this entry is not a canonical therapeutic target like an individual enzyme or receptor; it describes a pharmacological strategy targeting an entire metabolic process. The actual drug targets are specific enzymes within the pathway—such as IMPDH or other key synthetic enzymes—not the overall "pathway" itself. Therefore, while clinically relevant as a concept for drug action, it does not conform to standard definitions of molecular targets used for structured data extraction. If you need information on specific enzyme targets within this context—for example "inosine monophosphate dehydrogenase"—please specify further so that structured data can be provided at the appropriate molecular level[1][2].

Other names

Purine synthesis in T cellsDe novo purine biosynthesis in lymphocytesT cell proliferation via purine metabolism

Inhibition of de novo purine nucleotide synthesis, leading to suppression of DNA/RNA production and cell division in activated T lymphocytes[1][2].